The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $2.77 in the prior trading day, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $2.72, down -1.81%. In other words, the price has decreased by -$1.81 from its previous closing price. On the day, 1.16 million shares were traded. ACRS stock price reached its highest trading level at $2.9 during the session, while it also had its lowest trading level at $2.71.
Ratios:
Our goal is to gain a better understanding of ACRS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.03 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On November 19, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $2 to $7.
Jefferies Upgraded its Hold to Buy on November 19, 2024, whereas the target price for the stock was revised from $2 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Leonard Braden Michael bought 206,025 shares of ACRS for $256,357 on Aug 05 ’24. The 10% Owner now owns 14,250,000 shares after completing the transaction at $1.24 per share. On Aug 02 ’24, another insider, Leonard Braden Michael, who serves as the 10% Owner of the company, bought 167,544 shares for $1.29 each. As a result, the insider paid 216,400 and bolstered with 14,043,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 194292032 and an Enterprise Value of 68815160. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.05 while its Price-to-Book (P/B) ratio in mrq is 1.49. Its current Enterprise Value per Revenue stands at 2.541 whereas that against EBITDA is -1.106.
Stock Price History:
Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 1.89%, while the 200-Day Moving Average is calculated to be 73.51%.
Shares Statistics:
The stock has traded on average 2.33M shares per day over the past 3-months and 986060 shares per day over the last 10 days, according to various share statistics. A total of 71.42M shares are outstanding, with a floating share count of 59.91M. Insiders hold about 16.13% of the company’s shares, while institutions hold 75.64% stake in the company. Shares short for ACRS as of 1732838400 were 2480701 with a Short Ratio of 1.07, compared to 1730332800 on 2409457. Therefore, it implies a Short% of Shares Outstanding of 2480701 and a Short% of Float of 4.14.
